Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment ...

Endo, Inc. announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment of recurrence of Dupuytren contracture following surgical ...

American International Group Inc.'s successful bid to avoid covering litigation against opioid manufacturing giant ...

The global extended release drugs market is experiencing significant growth, projected to expand at a robust 11% CAGR from 2022 to 2032. With a valuation of USD 48 billion in 2022, the market is ...

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion.

Bengaluru: Mallinckrodt and Endo , drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their ...

Mallinckrodt, the Irish pharmaceutical company with its U.S. headquarters in Hazelwood, has agreed to merge with drug maker ...

Pharmaceutical companies Mallinckrodt Pharmaceuticals Plc and Endo Inc. have signed an agreement to create a combined company worth $6.7 billion. This is reported in a joint press release. Under the ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...